Northern Trust’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.88M | Buy |
612,141
+196,963
| +47% | +$1,000K | ﹤0.01% | 2774 |
|
|
2025
Q4 | $1.77M | Buy |
415,178
+25,493
| +7% | +$96.8K | ﹤0.01% | 3072 |
|
|
2025
Q3 | $1.24M | Sell |
389,685
-60,422
| -13% | -$136K | ﹤0.01% | 3294 |
|
|
2025
Q2 | $1.02M | Buy |
450,107
+299,475
| +199% | +$483K | ﹤0.01% | 3383 |
|
|
2025
Q1 | $95.8K | Hold |
150,632
| – | – | ﹤0.01% | 4128 |
|
|
2024
Q4 | $155K | Buy |
150,632
+20,746
| +16% | +$22.3K | ﹤0.01% | 4059 |
|
|
2024
Q3 | $153K | Sell |
129,886
-1,141
| -0.9% | -$1.45K | ﹤0.01% | 3957 |
|
|
2024
Q2 | $160K | Sell |
131,027
-3,091
| -2% | -$6.15K | ﹤0.01% | 3926 |
|
|
2024
Q1 | $292K | Sell |
134,118
-1,184
| -0.9% | -$2.19K | ﹤0.01% | 3754 |
|
|
2023
Q4 | $210K | Buy |
135,302
+15,383
| +13% | +$20.2K | ﹤0.01% | 3882 |
|
|
2023
Q3 | $155K | Buy |
119,919
+305
| +0.3% | +$480 | ﹤0.01% | 3901 |
|
|
2023
Q2 | $206K | Sell |
119,614
-386
| -0.3% | -$641 | ﹤0.01% | 3820 |
|
|
2023
Q1 | $181K | Buy |
120,000
+7,570
| +7% | +$17.1K | ﹤0.01% | 3896 |
|
|
2022
Q4 | $180K | Hold |
112,430
| – | – | ﹤0.01% | 3911 |
|
|
2022
Q3 | $163K | Sell |
112,430
-52
| -0% | -$80 | ﹤0.01% | 3955 |
|
|
2022
Q2 | $206K | Sell |
112,482
-460,953
| -80% | -$882K | ﹤0.01% | 3909 |
|
|
2022
Q1 | $1.53M | Sell |
573,435
-41,886
| -7% | -$161K | ﹤0.01% | 3234 |
|
|
2021
Q4 | $2.66M | Sell |
615,321
-39,365
| -6% | -$231K | ﹤0.01% | 3073 |
|
|
2021
Q3 | $3.33M | Sell |
654,686
-11,788
| -2% | -$63.1K | ﹤0.01% | 2997 |
|
|
2021
Q2 | $4.22M | Sell |
666,474
-18,451
| -3% | -$144K | ﹤0.01% | 2951 |
|
|
2021
Q1 | $5.29M | Buy |
684,925
+160,374
| +31% | +$1.27M | ﹤0.01% | 2710 |
|
|
2020
Q4 | $3.44M | Sell |
524,551
-5,833
| -1% | -$41.7K | ﹤0.01% | 2892 |
|
|
2020
Q3 | $3.53M | Sell |
530,384
-38,686
| -7% | -$287K | ﹤0.01% | 2747 |
|
|
2020
Q2 | $4.74M | Sell |
569,070
-6,350
| -1% | -$59K | ﹤0.01% | 2560 |
|
|
2020
Q1 | $4.41M | Buy |
575,420
+14,970
| +3% | +$104K | ﹤0.01% | 2381 |
|
|
2019
Q4 | $4.66M | Buy |
560,450
+1,730
| +0.3% | +$11.7K | ﹤0.01% | 2626 |
|
|
2019
Q3 | $4.12M | Buy |
558,720
+12,642
| +2% | +$125K | ﹤0.01% | 2662 |
|
|
2019
Q2 | $6.13M | Buy |
546,078
+4,058
| +0.7% | +$42.5K | ﹤0.01% | 2448 |
|
|
2019
Q1 | $5.83M | Buy |
542,020
+2,031
| +0.4% | +$30K | ﹤0.01% | 2468 |
|
|
2018
Q4 | $8.15M | Sell |
539,989
-423
| -0.1% | -$6.28K | ﹤0.01% | 2210 |
|
|
2018
Q3 | $10M | Buy |
540,412
+101,278
| +23% | +$2.31M | ﹤0.01% | 2254 |
|
|
2018
Q2 | $10M | Buy |
439,134
+116,119
| +36% | +$2.97M | ﹤0.01% | 2263 |
|
|
2018
Q1 | $9.19M | Sell |
323,015
-167
| -0.1% | -$4.77K | ﹤0.01% | 2225 |
|
|
2017
Q4 | $6.82M | Sell |
323,182
-6,329
| -2% | -$131K | ﹤0.01% | 2423 |
|
|
2017
Q3 | $5.99M | Buy |
329,511
+12,925
| +4% | +$202K | ﹤0.01% | 2520 |
|
|
2017
Q2 | $4.91M | Buy |
316,586
+84,602
| +36% | +$1.28M | ﹤0.01% | 2656 |
|
|
2017
Q1 | $4.01M | Sell |
231,984
-2,522
| -1% | -$33.2K | ﹤0.01% | 2692 |
|
|
2016
Q4 | $2.58M | Buy |
234,506
+18,182
| +8% | +$220K | ﹤0.01% | 2953 |
|
|
2016
Q3 | $3.39M | Buy |
216,324
+116,552
| +117% | +$1.41M | ﹤0.01% | 2780 |
|
|
2016
Q2 | $1.02M | Buy |
99,772
+26,055
| +35% | +$297K | ﹤0.01% | 3341 |
|
|
2016
Q1 | $951K | Buy |
73,717
+258
| +0.4% | +$3.58K | ﹤0.01% | 3271 |
|
|
2015
Q4 | $1.53M | Buy |
+73,459
| New | +$1.16M | ﹤0.01% | 3174 |
|
Other funds holding CTMX
KCM
PA
VA
VCM
Northern Trust's CTMX Position: Q1 2026 in Review
Northern Trust increased its CytomX Therapeutics (CTMX) stake by 47% in Q1 2026, buying an estimated $1,000K and bringing the position to 612,141 shares worth $2.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2774.
Northern Trust first reported a position in CTMX in Q4 2015 and has held it in 42 quarters since. The position peaked at $10M in Q2 2018. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.
- Northern Trust held 612,141 shares of CytomX Therapeutics worth $2.88M as of Q1 2026.
- Northern Trust bought 196,963 CytomX Therapeutics shares in Q1 2026, an estimated $1,000K.
- CytomX Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #2774 holding.
- Northern Trust first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 42 quarters since.
- Northern Trust's CytomX Therapeutics position peaked at $10M in Q2 2018.
- 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.